0000899243-19-000288.txt : 20190103 0000899243-19-000288.hdr.sgml : 20190103 20190103162253 ACCESSION NUMBER: 0000899243-19-000288 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190102 FILED AS OF DATE: 20190103 DATE AS OF CHANGE: 20190103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Klein Lawrence Otto CENTRAL INDEX KEY: 0001762583 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 19505803 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS AG STREET 2: 610 MAIN STREET 7TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-01-02 0 0001674416 CRISPR Therapeutics AG CRSP 0001762583 Klein Lawrence Otto C/O CRISPR THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Business Officer Stock Option (Right to Buy) 5.86 2026-03-01 Common Shares 83666 D Stock Option (Right to Buy) 12.57 2026-07-14 Common Shares 40000 D Stock Option (Right to Buy) 14.43 2027-06-14 Common Shares 31000 D Stock Option (Right to Buy) 17.66 2027-11-14 Common Shares 15000 D Stock Option (Right to Buy) 51.49 2028-03-06 Common Shares 60000 D The Reporting Person was granted an option to purchase 106,666 shares on March 2, 2016. 23,000 of such options were previously exercised, and the shares underlying those options were sold. 25% of this option became vested and fully exercisable on February 1, 2017, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the first day of each month thereafter. 100% of the shares shall vest in 48 equal monthly installments on the thirty-first day of each month, with the first vesting event on October 31, 2016 100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on July 15, 2017. 100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on December 15, 2017. 100% of the shares shall vest in 48 equal monthly installments on the seventh day of each month, with the first vesting event on April 7, 2018. Exhibit 24.1: Power of Attorney attached /s/ Michael Esposito, attorney-in-fact 2018-01-03 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT
                                                                    Exhibit 24.1

                               POWER OF ATTORNEY

      Know all by these presents, that the undersigned hereby constitutes and
appoints each of James R. Kasinger, Michael Esposito and Robert E. Puopolo,
signing singly, the undersigned's true and lawful attorney- in-fact to:

        (1)   execute for and on behalf of the undersigned, in the undersigned's
              capacity as an officer and/or director of CRISPR Therapeutics AG
              (the "Company"), (i) Form ID, including any attached documents, to
              effect the assignment of codes to the undersigned to be used in
              the transmission of information to the United States Securities
              and Exchange Commission using the EDGAR System, and (ii) Forms 3,
              4 and 5 and amendments thereto in accordance with Section 16(a) of
              the Securities Exchange Act of 1934, as amended, and the rules
              thereunder;

        (2)   do and perform any and all acts for and on behalf of the
              undersigned which may be necessary or desirable to complete and
              execute any such Form 3, 4 or 5 and amendments thereto and timely
              file such form with the United States Securities and Exchange
              Commission and any stock exchange or similar authority; and

        (3)   take any other action of any type whatsoever in connection with
              the foregoing which, in the opinion of such attorney-in-fact, may
              be of benefit to, in the best interest of, or legally required by,
              the undersigned, it being understood that the documents executed
              by such attorney-in-fact on behalf of the undersigned pursuant to
              this Power of Attorney shall be in such form and shall contain
              such terms and conditions as such attorney-in-fact may approve in
              such attorney-in-fact's discretion.

      The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended. The
undersigned hereby agrees to indemnify the attorney-in- fact and the Company
from and against any demand, damage, loss, cost or expense arising from any
false or misleading information provided by the undersigned to the attorney-in-
fact.

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney may be filed with the
United States Securities and Exchange Commission as a confirming statement of
the authority granted herein. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an executive
officer of, or legal counsel to the Company.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of December 17, 2018.


                                              /s/ Lawrence Otto Klein
                                        -----------------------------------
                                                      Signature


                                                 Lawrence Otto Klein
                                        -----------------------------------
                                                      Print Name